Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Биохимические предикторы атеросклеротического поражения коронарных артерий у больных с метаболическими нарушениями - Научно-практический журнал Cardioсоматика Том 6, №3 (2015)
Биохимические предикторы атеросклеротического поражения коронарных артерий у больных с метаболическими нарушениями
Суркичин Е.М., Шуваев И.П., Асымбекова Э.У., Мацкеплишвили С.Т. Биохимические предикторы атеросклеротического поражения коронарных артерий у больных с метаболическими нарушениями. КардиоСоматика. 2015; 6 (3): 33–37.
________________________________________________
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Аннотация
Метаболический синдром представляет собой сочетание основных факторов риска развития сердечно-сосудистых заболеваний, в основе развития которого лежит снижение чувствительности тканей к инсулину. До настоящего времени нет единого мнения о патогенезе взаимодействия основных составляющих его состояний. С открытием эндокринной функции жировой ткани появились данные, позволяющие предположить, что развитие и прогрессирование атеросклероза могут быть следствием дисбаланса адипокинов. Данная работа посвящена изучению взаимосвязи лептина и адипонектина с клинико-лабораторными показателями при наличии метаболических нарушений.
Ключевые слова: ишемическая болезнь сердца, метаболический синдром, адипонектин, лептин.
Key words: ischemic heart disease, metabolic syndrome, adiponectin, leptin.
Ключевые слова: ишемическая болезнь сердца, метаболический синдром, адипонектин, лептин.
________________________________________________
Key words: ischemic heart disease, metabolic syndrome, adiponectin, leptin.
Полный текст
Список литературы
1. Cook S, Weitzman M, Auinger P et al. Prevalence of a metabolic syndrome phenotype in adolescents: findings from the third National Health and Nutrition Examination Survey. Arch Pediatr Adolesc Med 2010; 157 (8): 821–7.
2. De Bakker J, Van Capelle F, Janse M et al. Slow conduction in the infracted human heart, “zigzag” course of activation. Circulation 1999; 88 (3): 915–26.
3. EGIR definition of metabolic syndrome. Diabet Med 2002; 16: 442–3.
4. Rasouli N, Kern PA. Adipocytokines and the metabolic complications of obesity rasouli and kern. J Clin Endocrinol Metab 2008; 93: 64–73.
5. Beltowski J. Leptin and atherosclerosis. Atherosclerosis 2006; 189: 47–60.
6. Wannamethee SG et al. Adipokines and risk of type 2 diabetes in older men. Diabet Care 2007; 30: 1200–5.
7. Grundy SM, Cleeman JI, Daniels SR et al. Diagnosis and management of the metabolic syndrome: an American Heart Association. National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2007; 112 (17): 2735–52.
8. Guzder RN, Gatling W, Mullee MA, Byrne CD. Impact of metabolic syndrome criteria on cardiovascular disease risk in people with newly diagnosed type 2 diabetes. Diabetologia 2006; 49 (10): 49–55.
9. Savage DB, Petersen KF, Shulman GI. Mechanisms of insulin resistance in humans and possible links with inflammation. Hypertension 2005; 45 (5): 828–33.
10. Sattar N, Gaw A, Scherbakova O et al. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation 2003; 108 (4): 414–9.
11. Оганов Р.Г., Мамедов М.Н. Школа по диагностике и лечению метаболического синдрома. М.: Медицинская книга, 2007. / Oganov R.G., Mamedov M.N. Shkola po diagnostike i lecheniiu metabolicheskogo sindroma. M.: Meditsinskaia kniga, 2007. [in Russian]
12. Chen YH, Lin SJ, Lin FY et al. High glucose impairs early and late endothelial progenitor cells by modifying nitric oxide-related but not oxidative stress-mediated mechanisms. Diabetes 2007; 56: 1559–68.
13. Shaw LJ, Marwick TH, Zoghbi WA et al. Why all the focus on cardiac imaging? [Editorial]. JACC Cardiovasc Imaging 2010; 3: 789–94. [PMID: 20633864]; 92 (5): 650–7.
14. Dandona P, Aljada A, Chaudhuri A et al. Metabolic syndrome: a comprehensive perspective based on interactions between obesity, diabetes, and inflammation. Circulation 2005; 111 (11): 1448–54.
15. Chandran M, Phillips SA, Ciaraldi T, Henry RR. Adiponectin: more than just another fat cell hormone? Diabetes Care 2003; 26 (8): 2442–50.
16. Vyssoulis G, Karpanou E, Adamopoulos D et al. Metabolic syndrome in patients with essential hypertension. Hypertension Unit, 1st Cardiology Department, Hippokration Hospital, Athens Medical School, Greece. Nutr Metab Cardiovasc Dis 2013; 23 (2): 109–14. Doi: 10.1016/j.numecd.2011.03.011.
17. Ghosh S, Karin M. Missing pieces in the NF-kappa-B puzzle. Cell 2002; 109 (Suppl.): S81–96.
18. Yamauchi T, Kamon J, Ito Y et al. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 2003; 423 (6941): 762–9.
19. Группа экспертов Всероссийского научного общества кардиологов. Рекомендации экспертов Всероссийского научного общества кардиологов по диагностике и лечению метаболического синдрома. Второй пересмотр. 2009. http://www.cardiosite.ru/recommendations/article / Gruppa ekspertov Vserossiiskogo nauchnogo obshchestva kardiologov. Rekomendatsii ekspertov Vserossiiskogo nauchnogo obshchestva kardiologov po diagnostike i lecheniiu metabolicheskogo sindroma. Vtoroi peresmotr. 2009. http://www.cardiosite.ru/recommendations/article [in Russian]
20. Маколкин В.И. и др. Необходимость гликемического контроля при лечении метаболического синдрома. Consillium Мedicum. 2007; 9 (5): 58–62. / Makolkin V.I. i dr. Neobkhodimost' glikemicheskogo kontrolia pri lechenii metabolicheskogo sindroma. Consillium Medicum. 2007; 9 (5): 58–62. [in Russian]
2. De Bakker J, Van Capelle F, Janse M et al. Slow conduction in the infracted human heart, “zigzag” course of activation. Circulation 1999; 88 (3): 915–26.
3. EGIR definition of metabolic syndrome. Diabet Med 2002; 16: 442–3.
4. Rasouli N, Kern PA. Adipocytokines and the metabolic complications of obesity rasouli and kern. J Clin Endocrinol Metab 2008; 93: 64–73.
5. Beltowski J. Leptin and atherosclerosis. Atherosclerosis 2006; 189: 47–60.
6. Wannamethee SG et al. Adipokines and risk of type 2 diabetes in older men. Diabet Care 2007; 30: 1200–5.
7. Grundy SM, Cleeman JI, Daniels SR et al. Diagnosis and management of the metabolic syndrome: an American Heart Association. National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2007; 112 (17): 2735–52.
8. Guzder RN, Gatling W, Mullee MA, Byrne CD. Impact of metabolic syndrome criteria on cardiovascular disease risk in people with newly diagnosed type 2 diabetes. Diabetologia 2006; 49 (10): 49–55.
9. Savage DB, Petersen KF, Shulman GI. Mechanisms of insulin resistance in humans and possible links with inflammation. Hypertension 2005; 45 (5): 828–33.
10. Sattar N, Gaw A, Scherbakova O et al. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation 2003; 108 (4): 414–9.
11. Oganov R.G., Mamedov M.N. Shkola po diagnostike i lecheniiu metabolicheskogo sindroma. M.: Meditsinskaia kniga, 2007. [in Russian]
12. Chen YH, Lin SJ, Lin FY et al. High glucose impairs early and late endothelial progenitor cells by modifying nitric oxide-related but not oxidative stress-mediated mechanisms. Diabetes 2007; 56: 1559–68.
13. Shaw LJ, Marwick TH, Zoghbi WA et al. Why all the focus on cardiac imaging? [Editorial]. JACC Cardiovasc Imaging 2010; 3: 789–94. [PMID: 20633864]; 92 (5): 650–7.
14. Dandona P, Aljada A, Chaudhuri A et al. Metabolic syndrome: a comprehensive perspective based on interactions between obesity, diabetes, and inflammation. Circulation 2005; 111 (11): 1448–54.
15. Chandran M, Phillips SA, Ciaraldi T, Henry RR. Adiponectin: more than just another fat cell hormone? Diabetes Care 2003; 26 (8): 2442–50.
16. Vyssoulis G, Karpanou E, Adamopoulos D et al. Metabolic syndrome in patients with essential hypertension. Hypertension Unit, 1st Cardiology Department, Hippokration Hospital, Athens Medical School, Greece. Nutr Metab Cardiovasc Dis 2013; 23 (2): 109–14. Doi: 10.1016/j.numecd.2011.03.011.
17. Ghosh S, Karin M. Missing pieces in the NF-kappa-B puzzle. Cell 2002; 109 (Suppl.): S81–96.
18. Yamauchi T, Kamon J, Ito Y et al. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 2003; 423 (6941): 762–9.
19. Gruppa ekspertov Vserossiiskogo nauchnogo obshchestva kardiologov. Rekomendatsii ekspertov Vserossiiskogo nauchnogo obshchestva kardiologov po diagnostike i lecheniiu metabolicheskogo sindroma. Vtoroi peresmotr. 2009. http://www.cardiosite.ru/recommendations/article [in Russian]
20. Makolkin V.I. i dr. Neobkhodimost' glikemicheskogo kontrolia pri lechenii metabolicheskogo sindroma. Consillium Medicum. 2007; 9 (5): 58–62. [in Russian]
2. De Bakker J, Van Capelle F, Janse M et al. Slow conduction in the infracted human heart, “zigzag” course of activation. Circulation 1999; 88 (3): 915–26.
3. EGIR definition of metabolic syndrome. Diabet Med 2002; 16: 442–3.
4. Rasouli N, Kern PA. Adipocytokines and the metabolic complications of obesity rasouli and kern. J Clin Endocrinol Metab 2008; 93: 64–73.
5. Beltowski J. Leptin and atherosclerosis. Atherosclerosis 2006; 189: 47–60.
6. Wannamethee SG et al. Adipokines and risk of type 2 diabetes in older men. Diabet Care 2007; 30: 1200–5.
7. Grundy SM, Cleeman JI, Daniels SR et al. Diagnosis and management of the metabolic syndrome: an American Heart Association. National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2007; 112 (17): 2735–52.
8. Guzder RN, Gatling W, Mullee MA, Byrne CD. Impact of metabolic syndrome criteria on cardiovascular disease risk in people with newly diagnosed type 2 diabetes. Diabetologia 2006; 49 (10): 49–55.
9. Savage DB, Petersen KF, Shulman GI. Mechanisms of insulin resistance in humans and possible links with inflammation. Hypertension 2005; 45 (5): 828–33.
10. Sattar N, Gaw A, Scherbakova O et al. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation 2003; 108 (4): 414–9.
11. Оганов Р.Г., Мамедов М.Н. Школа по диагностике и лечению метаболического синдрома. М.: Медицинская книга, 2007. / Oganov R.G., Mamedov M.N. Shkola po diagnostike i lecheniiu metabolicheskogo sindroma. M.: Meditsinskaia kniga, 2007. [in Russian]
12. Chen YH, Lin SJ, Lin FY et al. High glucose impairs early and late endothelial progenitor cells by modifying nitric oxide-related but not oxidative stress-mediated mechanisms. Diabetes 2007; 56: 1559–68.
13. Shaw LJ, Marwick TH, Zoghbi WA et al. Why all the focus on cardiac imaging? [Editorial]. JACC Cardiovasc Imaging 2010; 3: 789–94. [PMID: 20633864]; 92 (5): 650–7.
14. Dandona P, Aljada A, Chaudhuri A et al. Metabolic syndrome: a comprehensive perspective based on interactions between obesity, diabetes, and inflammation. Circulation 2005; 111 (11): 1448–54.
15. Chandran M, Phillips SA, Ciaraldi T, Henry RR. Adiponectin: more than just another fat cell hormone? Diabetes Care 2003; 26 (8): 2442–50.
16. Vyssoulis G, Karpanou E, Adamopoulos D et al. Metabolic syndrome in patients with essential hypertension. Hypertension Unit, 1st Cardiology Department, Hippokration Hospital, Athens Medical School, Greece. Nutr Metab Cardiovasc Dis 2013; 23 (2): 109–14. Doi: 10.1016/j.numecd.2011.03.011.
17. Ghosh S, Karin M. Missing pieces in the NF-kappa-B puzzle. Cell 2002; 109 (Suppl.): S81–96.
18. Yamauchi T, Kamon J, Ito Y et al. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 2003; 423 (6941): 762–9.
19. Группа экспертов Всероссийского научного общества кардиологов. Рекомендации экспертов Всероссийского научного общества кардиологов по диагностике и лечению метаболического синдрома. Второй пересмотр. 2009. http://www.cardiosite.ru/recommendations/article / Gruppa ekspertov Vserossiiskogo nauchnogo obshchestva kardiologov. Rekomendatsii ekspertov Vserossiiskogo nauchnogo obshchestva kardiologov po diagnostike i lecheniiu metabolicheskogo sindroma. Vtoroi peresmotr. 2009. http://www.cardiosite.ru/recommendations/article [in Russian]
20. Маколкин В.И. и др. Необходимость гликемического контроля при лечении метаболического синдрома. Consillium Мedicum. 2007; 9 (5): 58–62. / Makolkin V.I. i dr. Neobkhodimost' glikemicheskogo kontrolia pri lechenii metabolicheskogo sindroma. Consillium Medicum. 2007; 9 (5): 58–62. [in Russian]
________________________________________________
2. De Bakker J, Van Capelle F, Janse M et al. Slow conduction in the infracted human heart, “zigzag” course of activation. Circulation 1999; 88 (3): 915–26.
3. EGIR definition of metabolic syndrome. Diabet Med 2002; 16: 442–3.
4. Rasouli N, Kern PA. Adipocytokines and the metabolic complications of obesity rasouli and kern. J Clin Endocrinol Metab 2008; 93: 64–73.
5. Beltowski J. Leptin and atherosclerosis. Atherosclerosis 2006; 189: 47–60.
6. Wannamethee SG et al. Adipokines and risk of type 2 diabetes in older men. Diabet Care 2007; 30: 1200–5.
7. Grundy SM, Cleeman JI, Daniels SR et al. Diagnosis and management of the metabolic syndrome: an American Heart Association. National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2007; 112 (17): 2735–52.
8. Guzder RN, Gatling W, Mullee MA, Byrne CD. Impact of metabolic syndrome criteria on cardiovascular disease risk in people with newly diagnosed type 2 diabetes. Diabetologia 2006; 49 (10): 49–55.
9. Savage DB, Petersen KF, Shulman GI. Mechanisms of insulin resistance in humans and possible links with inflammation. Hypertension 2005; 45 (5): 828–33.
10. Sattar N, Gaw A, Scherbakova O et al. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation 2003; 108 (4): 414–9.
11. Oganov R.G., Mamedov M.N. Shkola po diagnostike i lecheniiu metabolicheskogo sindroma. M.: Meditsinskaia kniga, 2007. [in Russian]
12. Chen YH, Lin SJ, Lin FY et al. High glucose impairs early and late endothelial progenitor cells by modifying nitric oxide-related but not oxidative stress-mediated mechanisms. Diabetes 2007; 56: 1559–68.
13. Shaw LJ, Marwick TH, Zoghbi WA et al. Why all the focus on cardiac imaging? [Editorial]. JACC Cardiovasc Imaging 2010; 3: 789–94. [PMID: 20633864]; 92 (5): 650–7.
14. Dandona P, Aljada A, Chaudhuri A et al. Metabolic syndrome: a comprehensive perspective based on interactions between obesity, diabetes, and inflammation. Circulation 2005; 111 (11): 1448–54.
15. Chandran M, Phillips SA, Ciaraldi T, Henry RR. Adiponectin: more than just another fat cell hormone? Diabetes Care 2003; 26 (8): 2442–50.
16. Vyssoulis G, Karpanou E, Adamopoulos D et al. Metabolic syndrome in patients with essential hypertension. Hypertension Unit, 1st Cardiology Department, Hippokration Hospital, Athens Medical School, Greece. Nutr Metab Cardiovasc Dis 2013; 23 (2): 109–14. Doi: 10.1016/j.numecd.2011.03.011.
17. Ghosh S, Karin M. Missing pieces in the NF-kappa-B puzzle. Cell 2002; 109 (Suppl.): S81–96.
18. Yamauchi T, Kamon J, Ito Y et al. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 2003; 423 (6941): 762–9.
19. Gruppa ekspertov Vserossiiskogo nauchnogo obshchestva kardiologov. Rekomendatsii ekspertov Vserossiiskogo nauchnogo obshchestva kardiologov po diagnostike i lecheniiu metabolicheskogo sindroma. Vtoroi peresmotr. 2009. http://www.cardiosite.ru/recommendations/article [in Russian]
20. Makolkin V.I. i dr. Neobkhodimost' glikemicheskogo kontrolia pri lechenii metabolicheskogo sindroma. Consillium Medicum. 2007; 9 (5): 58–62. [in Russian]
Авторы
Е.М.Суркичин*, И.П.Шуваев, Э.У.Асымбекова, С.Т.Мацкеплишвили
ФГБНУ Научный центр сердечно-сосудистой хирургии им. А.Н.Бакулева. 121552, Россия, Москва, Рублевское ш., д. 135
*elena.surkichina@yandex.ru
A.N.Bakulev Scientific Center of Cardiovascular Surgery. 121552, Russian Federation, Moscow, Rublevskoe sh., d. 135
*elena.surkichina@yandex.ru
ФГБНУ Научный центр сердечно-сосудистой хирургии им. А.Н.Бакулева. 121552, Россия, Москва, Рублевское ш., д. 135
*elena.surkichina@yandex.ru
________________________________________________
A.N.Bakulev Scientific Center of Cardiovascular Surgery. 121552, Russian Federation, Moscow, Rublevskoe sh., d. 135
*elena.surkichina@yandex.ru
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.